NovePen Echo is the first insulin injection device combining half-unit dosing and memory function
Novo Nordisk has launched a new insulin injection device, NovePen Echo, in the United States. According to the company, this is the first and only pen device available in the US with half-unit dosing and a memory function that records the dose and time passed since the last injection.
The half-unit dose increments mean that patients will be able to better adjust their insulin dose, which is particularly useful for children with diabetes. In addition, 12 fun removable skins are available for a customized look, including kid-friendly designs.
"We and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately," said George McAvoy, vice president of the NovoLog brand team at Novo Nordisk, in a press statement.
Children with Diabetes founder Jeff Hitchcock stated that it is important that new, innovative tools continue to be developed so that children and caregivers have options. “NovePen Echo, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home."
NovePen Echo is already available in Europe, Canada and Israel.
Source:
Novo Nordisk
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.